Holen Sie sich die Stockscreener-App
235.08
2.49%
5.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$229.33
Offen:
$231
24-Stunden-Volumen:
181.35K
Relative Volume:
0.80
Marktkapitalisierung:
$4.71B
Einnahmen:
$274.48M
Nettoeinkommen (Verlust:
$153.56M
KGV:
31.87
EPS:
7.3755
Netto-Cashflow:
$114.06M
1W Leistung:
+13.12%
1M Leistung:
+1.63%
6M Leistung:
+14.01%
1J Leistung:
+131.35%
1-Tages-Spanne:
$228.65
$236.35
1-Wochen-Bereich:
$209.38
$236.35
52-Wochen-Spanne:
$98.89
$247.38
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
235.06 | 4.60B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.57 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.28 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | BofA Securities | Buy |
| 2025-12-09 | Eingeleitet | Citigroup | Buy |
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Ligand Pharmaceuticals Bets Big on Royalty Growth - TipRanks
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Files 8-K Announcing Amendment No. 1 to Agreement and Plan of Merger with XOMA Royalty Corporation 10 - Minichart
XOMA Royalty Corp Announces SEC Filing for Merger Agreement with Ligand Pharmaceuticals - Minichart
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals - Investing.com
Ligand Pharmaceuticals amends merger agreement with XOMA Royalty Corporation - Investing.com
XOMA Royalty Amends Ligand Merger Agreement, Adding Holding Company to Advance Acquisition - TradingView
XOMA Royalty (XOMA) adds new holding company to structure of Ligand acquisition - Stock Titan
Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company - TradingView
Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company - Stock Titan
Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Isthmus Partners LLC Reduces Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Live Share Prices and Trades. LGND.US Live Streaming Share Prices. - London South East
Orchestra BioMed Secures Ligand Funding for Pivotal Trials - MyChesCo
Ligand Pharmaceuticals Insider Sold Shares Worth $563,080, According to a Recent SEC Filing - Moomoo
Ligand Pharmaceuticals' (NASDAQ:LGND) Strong Earnings Are Of Good Quality - Yahoo Finance
Travere, Ligand Pharma announce FDA label expansion for Filspari - MSN
Ligand Pharmaceuticals director sells $563,079 in shares By Investing.com - Investing.com India
LGND director sells 2,501 shares after option exercise | LGND Insider Trading - Stock Titan
Ligand Pharmaceuticals director sells $563,079 in shares - Investing.com
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million - MSN
TradingKey - TradingKey
Ligand Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
John Kozarich sells shares; LGND (NASDAQ: LGND) option exercise for 1,575 shares - Stock Titan
RBC Capital Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $262 - Moomoo
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2026 Earnings Call Transcript - Insider Monkey
Ligand-Xoma Deal Would Combine Two Royalty Aggregators -- WSJ - Moomoo
Kozarich files Form 144 to sell 459 shares (NASDAQ: LGND) - Stock Titan
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $262 - 富途牛牛
Ligand (LGND) Q1 2026 Earnings Call Transcript - The Globe and Mail
A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination - Yahoo Finance
State of New Jersey Common Pension Fund D Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals’ Earnings Call Signals Scaled Royalty Push - TipRanks
LGND: 1Q:26 Results Highlight Breadth of Portfolio - Yahoo Finance
UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Q1 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
LGND Maintained by RBC Capital -- Price Target Raised to $262 - GuruFocus
Ligand (NASDAQ: LGND) lifts Q1 2026 royalties but books Pelthos fair value loss - Stock Titan
RBC Raises Price Target on Ligand Pharmaceuticals to $262 From $252, Keeps Outperform Rating - marketscreener.com
Ligand Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - Moomoo
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $262 - Moomoo
Ligand Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Ligand (LGND) Completes $15M Investment in Orchestra BioMed - GuruFocus
MSN Money - MSN
Earnings call transcript: Ligand Pharmaceuticals Q1 2026 results miss forecasts - Investing.com Canada
Ligand Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ligand Pharmaceuticals Reports $32.4 Million in Revenue for Q1 2026 - geneonline.com
Ligand Pharmaceuticals Incorporated : First Quarter 2026 Earnings Webcast - marketscreener.com
Ligand: Q1 Earnings Snapshot - KTVB
Ligand holds $779M, keeps 2026 outlook with XOMA deal set for Q3 - Stock Titan
Ligand (LGND) Q1 2026 royalty revenue jumps 56% as guidance reaffirmed - Stock Titan
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ligand Pharmaceuticals Inc-Aktie (LGND) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KOZARICH JOHN W | Director |
May 12 '26 |
Option Exercise |
69.51 |
459 |
31,905 |
42,245 |
| KOZARICH JOHN W | Director |
May 13 '26 |
Sale |
223.50 |
1,575 |
352,012 |
41,786 |
| KOZARICH JOHN W | Director |
May 01 '26 |
Sale |
231.80 |
467 |
108,251 |
41,786 |
| KOZARICH JOHN W | Director |
May 12 '26 |
Sale |
224.00 |
459 |
102,816 |
41,786 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):